Take a Look Into Our Market Access Work Market AccessMarket ResearchOncology Updates Take a Look Into Our Market Access Work
Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB? Market AccessMarket ResearchOncology Updates Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB?
Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer Approval BlogMedical CommunicationsOncology Updates Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer
Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma Approval BlogMedical CommunicationsOncology Updates Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma
Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma Approval BlogMedical CommunicationsOncology Updates Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma
Leveraging Innovation Centers to Re-prime the Development Pump! Oncology Updates Leveraging Innovation Centers to Re-prime the Development Pump!
Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC Approval BlogMedical CommunicationsOncology Updates Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC
Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma Approval BlogMedical CommunicationsOncology Updates Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma
Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Approval BlogMedical CommunicationsOncology Updates Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Blinatumomab for Patients with MRD-positive B-cell Precursor ALL Approval BlogMedical CommunicationsOncology Updates Blinatumomab for Patients with MRD-positive B-cell Precursor ALL
